Belite Bio (BLTE) Operating Expenses (2022 - 2026)
Belite Bio (BLTE) posted quarterly Operating Expenses of $32.7 million for Q1 2026, up 110.63% year-over-year from $15.5 million in Q1 2025, and down 99.88% quarter-over-quarter from $28.1 billion in Q4 2025.
Belite Bio (BLTE) Operating Expenses (2022 - 2026) Analysis & Trends
Belite Bio's Operating Expenses history runs 5 years deep, the most recent figure standing at $32.7 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 110.63% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at $68.7 billion (up 116.91% YoY), while the FY2025 annual figure was $84.2 million, up 110.54% from the prior year.
- Operating Expenses for Q1 2026 stood at $32.7 million, down from $28.1 billion in the prior quarter.
- The five-year high for Operating Expenses was $28.1 billion in Q4 2025, with the low at $6.7 million in Q4 2022.
- The 5-year median for Operating Expenses is $6.9 billion (2023), against an average of $8.0 billion.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 164630.41% in 2024, then plunged 99.81% in 2025.
- Belite Bio's Operating Expenses stood at $6.7 million in 2022, then grew by 3.48% to $7.0 million in 2023, then soared by 164630.41% to $11.5 billion in 2024, then soared by 145.06% to $28.1 billion in 2025, then plunged by 99.88% to $32.7 million in 2026.
- Business Quant data shows BLTE's Operating Expenses at $32.7 million in Q1 2026, $28.1 billion in Q4 2025, and $23.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | 32.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.68 Mn |
| Dec 31, 2025 | 28.08 Bn |
| Sep 30, 2025 | 23.02 Bn |
| Jun 30, 2025 | 17.60 Bn |
| Mar 31, 2025 | 15.52 Mn |
| Dec 31, 2024 | 11.46 Bn |
| Sep 30, 2024 | 9.74 Bn |
| Jun 30, 2024 | 10.47 Bn |
| Mar 31, 2024 | 8.33 Bn |
| Dec 31, 2023 | 6.96 Mn |
| Sep 30, 2023 | 10.96 Mn |
| Jun 30, 2023 | 6.87 Bn |
| Mar 31, 2023 | 6.88 Bn |
| Dec 31, 2022 | 6.72 Mn |
| Sep 30, 2022 | 2.54 Bn |
| Jun 30, 2022 | 2.51 Bn |